Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations

[1] Kaplon H(2022)Antibodies to watch in 2022 MAbs 14 2014296-608

[2] Chenoweth A(2019)Bispecific antibodies: a mechanistic review of the pipeline Nat Rev Drug Discov 18 585-1207

[3] Crescioli S(2010)Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization Nat Biotechnol 28 1203-151

[4] Reichert JM(2016)Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation Immunol Rev 270 132-392

[5] Labrijn AF(2020)Exploitation of elevated extracellular ATP to specifically direct antibody to tumor microenvironment Cell Rep 33 93-29741

[6] Janmaat ML(2022)Antibody drug conjugate: the “biological missile” for targeted cancer therapy Signal Transduct Target Ther 7 385-23524

[7] Reichert JM(2010)Reduced elimination of IgG antibodies by engineering the variable region Protein Eng Des Sel 23 29732-159

[8] Parren P(2015)Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics J Biol Chem 290 23514-6153

[9] Igawa T(2006)Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn) J Biol Chem 281 157-e679

[10] Ishii S(2010)Enhanced antibody half-life improves in vivo activity Nat Biotechnol 28 6147-66

[1] Kaplon H(2022)Antibodies to watch in 2022 MAbs 14 2014296-608

[2] Chenoweth A(2019)Bispecific antibodies: a mechanistic review of the pipeline Nat Rev Drug Discov 18 585-1207

[3] Crescioli S(2010)Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization Nat Biotechnol 28 1203-151

[4] Reichert JM(2016)Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation Immunol Rev 270 132-392

[5] Labrijn AF(2020)Exploitation of elevated extracellular ATP to specifically direct antibody to tumor microenvironment Cell Rep 33 93-29741

[6] Janmaat ML(2022)Antibody drug conjugate: the “biological missile” for targeted cancer therapy Signal Transduct Target Ther 7 385-23524

[7] Reichert JM(2010)Reduced elimination of IgG antibodies by engineering the variable region Protein Eng Des Sel 23 29732-159

[8] Parren P(2015)Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics J Biol Chem 290 23514-6153

[9] Igawa T(2006)Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn) J Biol Chem 281 157-e679

[10] Ishii S(2010)Enhanced antibody half-life improves in vivo activity Nat Biotechnol 28 6147-66